Zentalis Pharmaceuticals ZNTL 深 沪
等待开盘 02-05 09:30:00 美东时间
2.55
-0.270
-9.57%
华盛通- 最 高2.85
- 今 开2.84
- 成交量 75.85万股
- 最 低 2.505
- 昨 收 2.82
- 总市值 1.84亿
- 52周最高 3.95
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.01
- 委 比 -94.88%
- 总股本 7213.55万
- 历史最高 87.19
- 量 比 1.09
- 振 幅 12.23%
- 历史最低 1.01
- 每 手 1
- 风险率 0.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Zentalis outlines 2026 milestones for azenosertib program
Zentalis Pharmaceuticals ( ($ZNTL) ) has provided an update. On January 6, 2026...
01-10 06:49
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares moved upwards by 14.1% to...
01-09 05:06
美股牛股 | AI引爆涨价潮！SanDisk飙升超27%；Ventyx 涨超28%
AI引爆涨价潮！Sandisk飙升超27%；有望获礼来超10亿美元收购，Ventyx 涨超28%>>
01-07 15:44
Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026
Zentalis Pharmaceuticals provided a corporate update highlighting key milestones for 2026, including expected topline data from the DENALI Part 2 trial and initiation of the ASPENOVA Phase 3 trial for azenosertib, a WEE1 inhibitor targeting Cyclin E1-positive platinum-resistant ovarian cancer (PROC). The company aims to support accelerated approval and plans to evaluate azenosertib in additional ovarian cancer settings, backed by a strong financi...
01-06 13:00
美股大行评级 | 富国银行上调AMD目标价升至345美元；花旗上调礼来目标价升至1500美元；巴克莱上调腾讯音乐目标价升至28美元
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从12美元升至15美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至107美元
2025-11-13 09:58
Morgan Stanley Maintains Equal-Weight on Zentalis Pharma, Lowers Price Target to $4
Morgan Stanley analyst Matthew Harrison maintains Zentalis Pharma (NASDAQ:ZNTL) with a Equal-Weight and lowers the price target from $8 to $4.
2025-11-13 01:25
Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress
Zentalis Pharmaceuticals announced the continuation of its Phase 2 DENALI trial of azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer (PROC), targeting topline data by end of 2026, with potential for accelerated FDA approval. The company reported $280.7 million in cash, supporting operations into late 2027, along with decreased R&D and G&A expenses. Additionally, the TETON trial in uterine serous carcinoma completed enrollment.
2025-11-10 21:05
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals granted non-qualified stock options to purchase 17,000 shares to a newly hired employee under the 2022 Inducement Plan. The options have an exercise price of $1.44 and vest over four years. Zentalis is developing a potentially first-in-class WEE1 inhibitor for ovarian cancer patients.
2025-11-03 22:25
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Zentalis Pharmaceuticals announced that its management team will participate in two upcoming investor conferences: Guggenheim's 2nd Annual Healthcare Innovation Conference in Boston on November 11, 2025, and Stifel's 2025 Healthcare Conference in New York on November 12, 2025. Zentalis is developing azenosertib (ZN-c3), a potential first-in-class WEE1 inhibitor for ovarian cancer. More details about the events and presentations are available on t...
2025-11-03 13:15
Zentalis Pharmaceuticals Announces Four Abstracts On Its Wee1 Inhibitor, Azenosertib, Have Been Accepted For Poster Presentations At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics October 22–26, 2025, In Boston, Massachusetts.
Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today
2025-10-14 04:07
